Tang Capital Management LLC Buys Shares of 15,681 Molecular Partners AG (NASDAQ:MOLN)
Tang Capital Management LLC Buys Shares of 15,681 Molecular Partners AG (NASDAQ:MOLN)
Tang Capital Management LLC bought a new stake in shares of Molecular Partners AG (NASDAQ:MOLN – Get Rating) in the 3rd quarter, HoldingsChannel.com reports. The institutional investor bought 15,681 shares of the company's stock, valued at approximately $105,000.
唐資本管理有限責任公司在第三季度購買了分子合作夥伴 AG 股份的新股份 (納斯達克:莫爾恩 — 獲得評級), Holdingschannel.com 報告.該機構投資者購買了該公司股票的 15,681 股，價值約為 105,000 美元。
Separately, Federated Hermes Inc. grew its position in Molecular Partners by 94.2% in the first quarter. Federated Hermes Inc. now owns 457,037 shares of the company's stock valued at $9,264,000 after acquiring an additional 221,743 shares during the period. 2.56% of the stock is owned by hedge funds and other institutional investors.
另外，聯邦愛馬仕公司在第一季度增長了 94.2％ 在分子合作夥伴中的地位。聯邦愛馬仕股份有限公司現在擁有該公司股票的 457,037 股，價值 9,264,000 美元，在此期間增加了 221,743 股。2.56% 的股票由對沖基金和其他機構投資者擁有。
Molecular Partners Price Performance
分子夥伴價格表現
Molecular Partners stock traded up $0.20 on Wednesday, reaching $6.30. The company's stock had a trading volume of 238 shares, compared to its average volume of 2,403. Molecular Partners AG has a twelve month low of $5.50 and a twelve month high of $25.88. The business's fifty day moving average price is $6.55 and its 200 day moving average price is $6.45.
分子合作夥伴股票在周三上漲 0.20 美元，達到 6.30 美元。該公司的股票交易量為 238 股，而平均交易量為 2,403 股。分子合作夥伴股份公司擁有十二個月低點 5.50 美元，十二個月高點為 25.88 美元。該企業的五十天移動平均價格為 6.55 美元，其 200 日移動平均價格為 6.45 美元。
Molecular Partners Profile
分子夥伴概況
(Get Rating)
(取得評分)
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus.
分子合作夥伴公司是一家臨床階段的生物製藥公司，專注於治療性蛋白質的發現，開發和商業化。其候選產品包括阿比帕爾（Abicipar），DarPin 治療候選人，該藥物正處於 III 期臨床試驗中，用於治療新生血管濕年齡相關性黃斑變性以及糖尿病性黃斑水腫；以及用於 SARS-CoV-2 病毒的多特異性 Darpin 治療候選人 MP0420。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Molecular Partners (MOLN)
- Should You Park Some Capital with Casey's General Stores?
- Crowdstrike Stock: While The Iron Is Hot!
- Occidental Petroleum: What Would Warren Buffett Do?
- Is Unity Software Earnings Fallout a Buying Opportunity?
- Why Wall Street Is Still So Constructive on Aecom Stock
- 免費索取分子夥伴研究報告
- 你應該停放一些資本與凱西的綜合商店?
- 群眾罷工股票：雖然鐵是熱的！
- 西方石油：沃倫·巴菲特會做什麼？
- 是統一軟件盈利輻射購買機會?
- 為什麼華爾街在 Aecom 股票上仍然如此建設性
Want to see what other hedge funds are holding MOLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Molecular Partners AG (NASDAQ:MOLN – Get Rating).
想看看還有哪些對沖基金持有 MOLN？ 訪問 Holdingschannel.com 以獲取分子合作夥伴股份公司（納斯達克：莫爾恩-獲取評級）的最新文件和內幕交易。
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.
每日接收分子合作夥伴的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收分子合作夥伴和相關公司的最新新聞和分析師評級的簡要每日摘要。